Office-Based Buprenorphine Treatment

Abstract

Opiate addiction is a serious global health issue that profoundly impacts the welfare of populations around the world. Opioid addiction affects an estimated 1.9 million individuals in the United States alone, stimulating a rise in treatment options such as medication-assisted treatment with buprenorphine. When combined with counseling and relapse prevention groups, medication-assisted treatment has proven to be an effective office-based opioid treatment for opiate dependence. Office-based opioid treatment has broadened access to treatment of opioid dependence, has decreased the risk for overdose, and is effective for reducing cravings and opioid use at proper dosing levels. However, treatment retention and relapse remain significant challenges. The purpose of this study was to identify characteristics predictive of retention in treatment time of opioid-dependent individuals receiving office-based buprenorphine treatment. The records of individuals enrolled in a public health office buprenorphine clinic (n = 350) were analyzed to determine retention time in treatment and whether retention time varied by selected individual variables. Participants in the study had a cumulative predicted retention time on buprenorphine of 65% at 30 days, 35% at 6 months, 25% at 12 months, and 18% at 18 months.

Are we ready to manage an opioid epidemic in the intensive care unit?

“…Buprenorphine, a mu receptor partial agonist, kappa antagonist, delta agonist, and ORl-1 receptor partial agonist, is commonly used for opioid use disorder as maintenance therapy. the peculiar pharmacological profile (only a ceiling effect on respiratory depression, not analgesic properties) attracts physicians to use buprenorphine in an office-based setting, unlike methadone, which is mainly prescribed in authorized deaddiction centres [ 62 ]. Buprenorphine has less toxicity due to overdose.…”

Hyperbaric Oxygen to Assist Adults With Opioid Use Disorder in Reducing Methadone Dose

“…Federal guidelines have established medications for addiction treatment (MAT) as the gold standard for preventing death from opioid overdose (Substance Abuse and Mental Health Services Administration, 2015). Although the number of adults receiving MAT for opioid use disorder (OUD) in the United States has climbed to more than 350,000 adults (Alderks, 2017), successful recovery remains suboptimal (Naji et al, 2016; Noe & Keller, 2020).…”